NUTRIBAND INC (NTRB) Fundamental Analysis & Valuation
NASDAQ:NTRB • US67092M2089
Current stock price
3.69 USD
-0.26 (-6.58%)
At close:
3.76 USD
+0.07 (+1.9%)
After Hours:
This NTRB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NTRB Profitability Analysis
1.1 Basic Checks
- In the past year NTRB has reported negative net income.
- In the past year NTRB has reported a negative cash flow from operations.
- In the past 5 years NTRB always reported negative net income.
- NTRB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -410.87%, NTRB is not doing good in the industry: 92.75% of the companies in the same industry are doing better.
- NTRB has a worse Return On Equity (-458.24%) than 79.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -410.87% | ||
| ROE | -458.24% | ||
| ROIC | N/A |
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NTRB has a Gross Margin of 33.50%. This is comparable to the rest of the industry: NTRB outperforms 59.59% of its industry peers.
- In the last couple of years the Gross Margin of NTRB has remained more or less at the same level.
- NTRB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
2. NTRB Health Analysis
2.1 Basic Checks
- NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
- NTRB has more shares outstanding than it did 1 year ago.
- NTRB has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for NTRB has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 20.72 indicates that NTRB is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 20.72, NTRB belongs to the top of the industry, outperforming 90.67% of the companies in the same industry.
- A Debt/Equity ratio of 0.01 indicates that NTRB is not too dependend on debt financing.
- NTRB has a Debt to Equity ratio (0.01) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 20.72 |
ROIC/WACCN/A
WACC9.52%
2.3 Liquidity
- A Current Ratio of 7.53 indicates that NTRB has no problem at all paying its short term obligations.
- NTRB's Current ratio of 7.53 is fine compared to the rest of the industry. NTRB outperforms 75.65% of its industry peers.
- NTRB has a Quick Ratio of 7.35. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
- NTRB has a Quick ratio of 7.35. This is in the better half of the industry: NTRB outperforms 75.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.53 | ||
| Quick Ratio | 7.35 |
3. NTRB Growth Analysis
3.1 Past
- NTRB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -331.58%.
- The Revenue has grown by 12.69% in the past year. This is quite good.
- NTRB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.99% yearly.
EPS 1Y (TTM)-331.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.78%
Revenue 1Y (TTM)12.69%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%-46.42%
3.2 Future
- The Earnings Per Share is expected to grow by 100.83% on average over the next years. This is a very strong growth
- Based on estimates for the next years, NTRB will show a very strong growth in Revenue. The Revenue will grow by 334.01% on average per year.
EPS Next Y-933.33%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue Next Year23.72%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. NTRB Valuation Analysis
4.1 Price/Earnings Ratio
- NTRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- A Price/Forward Earnings ratio of 2.49 indicates a rather cheap valuation of NTRB.
- 97.41% of the companies in the same industry are more expensive than NTRB, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 23.28. NTRB is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.49 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as NTRB's earnings are expected to grow with 100.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y110.16%
EPS Next 3Y100.83%
5. NTRB Dividend Analysis
5.1 Amount
- NTRB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NTRB Fundamentals: All Metrics, Ratios and Statistics
3.69
-0.26 (-6.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-11 2025-12-11/bmo
Earnings (Next)04-27 2026-04-27/amc
Inst Owners2.99%
Inst Owner Change-2.66%
Ins Owners59.53%
Ins Owner Change0%
Market Cap44.91M
Revenue(TTM)2.28M
Net Income(TTM)-34.59M
Analysts82.86
Price Target15.3 (314.63%)
Short Float %6.51%
Short Ratio13.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.73%
Min EPS beat(2)-3.81%
Max EPS beat(2)85.27%
EPS beat(4)2
Avg EPS beat(4)-52.18%
Min EPS beat(4)-316.67%
Max EPS beat(4)85.27%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-31.62%
Min Revenue beat(2)-49.75%
Max Revenue beat(2)-13.5%
Revenue beat(4)0
Avg Revenue beat(4)-19.02%
Min Revenue beat(4)-49.75%
Max Revenue beat(4)-1.6%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.49 | ||
| P/S | 19.71 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.95 | ||
| P/tB | 8 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.13
EYN/A
EPS(NY)1.48
Fwd EY40.08%
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.19
BVpS0.62
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -410.87% | ||
| ROE | -458.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.5% | ||
| FCFM | N/A |
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.3% | ||
| Cap/Sales | 0.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.53 | ||
| Quick Ratio | 7.35 | ||
| Altman-Z | 20.72 |
F-Score5
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-331.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.78%
EPS Next Y-933.33%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue 1Y (TTM)12.69%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%-46.42%
Revenue Next Year23.72%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
EBIT growth 1Y-53.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.72%
OCF growth 3YN/A
OCF growth 5YN/A
NUTRIBAND INC / NTRB Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for NUTRIBAND INC?
ChartMill assigns a fundamental rating of 4 / 10 to NTRB.
What is the valuation status for NTRB stock?
ChartMill assigns a valuation rating of 3 / 10 to NUTRIBAND INC (NTRB). This can be considered as Overvalued.
Can you provide the profitability details for NUTRIBAND INC?
NUTRIBAND INC (NTRB) has a profitability rating of 1 / 10.
What is the expected EPS growth for NUTRIBAND INC (NTRB) stock?
The Earnings per Share (EPS) of NUTRIBAND INC (NTRB) is expected to decline by -933.33% in the next year.